{"protocolSection": {"identificationModule": {"nctId": "NCT02625922", "orgStudyIdInfo": {"id": "CRLX030A2211"}, "secondaryIdInfos": [{"id": "2015-002673-38", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure", "officialTitle": "A Multicenter, Randomized, Double-blind, Crossover Placebo-controlled Phase II Study to Assess the Effect of Serelaxin Versus Placebo on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure After Exercise When Used in Addition to Standard of Care", "acronym": "RELAX-Cardio"}, "statusModule": {"statusVerifiedDate": "2018-01", "overallStatus": "TERMINATED", "whyStopped": "In view of outcome of RELAX-AHF-2 trial, the entire RLX030A project was decided to be terminated.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-02-05"}, "primaryCompletionDateStruct": {"date": "2017-01-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-01-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-12-03", "studyFirstSubmitQcDate": "2015-12-07", "studyFirstPostDateStruct": {"date": "2015-12-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-01-11", "resultsFirstSubmitQcDate": "2018-01-11", "resultsFirstPostDateStruct": {"date": "2018-09-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-01-11", "lastUpdatePostDateStruct": {"date": "2018-09-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with CHF after an exercise testing session."}, "conditionsModule": {"conditions": ["Chronic Heart Failure"], "keywords": ["Serelaxin,", "Chronic heart failure,", "Spiroergometry,", "Troponin,", "New York Heart Association (NYHA) functional Class II/III,", "Left ventricular ejection fraction,"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 26, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Serelaxin followed by Placebo", "type": "EXPERIMENTAL", "description": "On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 \u00b1 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.", "interventionNames": ["Drug: Serelaxin", "Drug: Placebo"]}, {"label": "Placebo followed by Serelaxin", "type": "EXPERIMENTAL", "description": "On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 \u00b1 1-day washout, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.", "interventionNames": ["Drug: Serelaxin", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Serelaxin", "description": "Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen", "armGroupLabels": ["Placebo followed by Serelaxin", "Serelaxin followed by Placebo"], "otherNames": ["RLX030"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo i.v infusion", "armGroupLabels": ["Placebo followed by Serelaxin", "Serelaxin followed by Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Geometric Mean of High Sensitivity Cardiac Troponin I (Hs-cTnI) Concentration After Exercise Compared to Placebo", "description": "This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.", "timeFrame": "Baseline, up to 7 hours after the start of an exercise testing session on treatment period 1 (Day 1) and treatment period 2 (Day 15+/- 1)"}], "secondaryOutcomes": [{"measure": "Geometric Mean of High Sensitivity Cardiac Troponin I (Hs-cTnI) Concentrations After Exercise Compared to Placebo at 4 and 5 Hours", "description": "This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.", "timeFrame": "4 and 5 hours after exercise testing session"}, {"measure": "Log-transformed Concentration of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations Compared to Placebo", "description": "This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.", "timeFrame": "Baseline, up to 7 hours after the start of an exercise testing session on treatment period 1 (Day 1) and treatment period 2 (Day 15 +/- 1)"}, {"measure": "Log-transformed Concentration Values of Heart-type Fatty Acid-binding Protein (H-FABP) Concentrations Compared to Placebo", "description": "This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.", "timeFrame": "Baseline, up to 7 hours after the start of an exercise testing session on treatment period 1 (Day 1) and treatment period 2 (Day 15 +/- 1)"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* Male or female \u2265 18 years of age, with body weight \u2264 160 Kg\n* Diagnosis of stable CHF:\n\n  * New York Heart Association (NYHA) functional Class II/III.\n  * Receiving guideline-recommended treatment for CHF.\n* Left ventricular ejection fraction \\< 45%, obtained within the last 3 months prior to screening.\n* NT-proBNP \\> 300 ng/L in sinus rhythm or \\> 900 ng/L if not in sinus rhythm (determined locally).\n* Ability to exercise for at least 10 to 12 minutes based on investigator's judgment.\n* Systolic BP \u2265 125 mmHg at randomization\n* Renal function defined as an eGFR of \u2265 25 mL/min/1.73 m\\^2 at screening (sMDRD formula).\n\nKey Exclusion Criteria:\n\n* Dyspnea primarily due to non-cardiac causes.\n* Increased risk of developing hypotension during vasodilator therapy according to investigators judgement.\n* Any contraindication for exercise testing and spirometry.\n* Stopping of the spiroergometry at screening according to the stopping rules, unless the patient has reached maximum exercise capacity defined as carbon dioxide production/oxygen consumption (VCO2/VO2) \\> 1.05.\n* Change in guideline-recommended CHF treatment within 1 month prior to screening.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Greifswald", "state": "Mecklenburg Vorpommern", "zip": "17475", "country": "Germany", "geoPoint": {"lat": 54.09311, "lon": 13.38786}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Dresden", "zip": "01307", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Novartis Investigative Site", "city": "Muenchen", "zip": "80636", "country": "Germany", "geoPoint": {"lat": 51.60698, "lon": 13.31243}}, {"facility": "Novartis Investigative Site", "city": "Muenchen", "zip": "81675", "country": "Germany", "geoPoint": {"lat": 51.60698, "lon": 13.31243}}, {"facility": "Novartis Investigative Site", "city": "Basel", "zip": "4031", "country": "Switzerland", "geoPoint": {"lat": 47.55839, "lon": 7.57327}}, {"facility": "Novartis Investigative Site", "city": "Hull", "zip": "HU16 5JQ", "country": "United Kingdom", "geoPoint": {"lat": 53.7446, "lon": -0.33525}}, {"facility": "Novartis Investigative Site", "city": "London", "zip": "SW 6NP", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Novartis Investigative Site", "city": "Tyne And Wear", "zip": "NE2 4HH", "country": "United Kingdom"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "There were total 11 centers from 3 countries. (Germany-6, Switzerland-1, and the United Kingdom-4).", "groups": [{"id": "FG000", "title": "Serelaxin-Placebo", "description": "Subjects received serelaxin in Treatment Period 1 and placebo in Treatment Period 2.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion."}, {"id": "FG001", "title": "Placebo-Serelaxin", "description": "Subjects received placebo in Treatment Period 1 and serelaxin in Treatment Period 2.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "Completed Treatment Period 1", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Completed Treatment Period 2", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Non-availability of IMP", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Systolic blood pressure < 125 mmHg", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The full analysis set (FAS) consisted of all randomized patients.", "groups": [{"id": "BG000", "title": "Serelaxin-Placebo", "description": "Subjects received serelaxin in Treatment Period 1 and placebo in Treatment Period 2.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion."}, {"id": "BG001", "title": "Placebo-Serelaxin", "description": "Subjects received placebo in Treatment Period 1 and serelaxin in Treatment Period 2.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "26"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74.7", "spread": "7.62"}, {"groupId": "BG001", "value": "66.5", "spread": "13.89"}, {"groupId": "BG002", "value": "70.9", "spread": "11.51"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "23"}]}]}]}, {"title": "Weight (kg)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram (kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "84.5", "spread": "14.19"}, {"groupId": "BG001", "value": "83.9", "spread": "17.85"}, {"groupId": "BG002", "value": "84.2", "spread": "15.65"}]}]}]}, {"title": "Childbearing status", "description": "Number of post-menopausal participants.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Geometric Mean of High Sensitivity Cardiac Troponin I (Hs-cTnI) Concentration After Exercise Compared to Placebo", "description": "This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.", "populationDescription": "The primary analysis of mixed model repeated measures was not performed because the validation of the primary endpoint variable hs-cTnI assay (Singulex Erenna\u00ae) was not completed because of the early termination of the study and, therefore, hs-cTnI was not analyzed.", "reportingStatus": "POSTED", "timeFrame": "Baseline, up to 7 hours after the start of an exercise testing session on treatment period 1 (Day 1) and treatment period 2 (Day 15+/- 1)", "groups": [{"id": "OG000", "title": "Serelaxin-Placebo", "description": "Subjects received serelaxin in Treatment Period 1 and placebo in Treatment Period 2.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion."}, {"id": "OG001", "title": "Placebo-Serelaxin", "description": "Subjects received placebo in Treatment Period 1 and serelaxin in Treatment Period 2.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Geometric Mean of High Sensitivity Cardiac Troponin I (Hs-cTnI) Concentrations After Exercise Compared to Placebo at 4 and 5 Hours", "description": "This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.", "populationDescription": "The objective was not analyzed because the validation of the hs-cTnI Singulex Erenna\u00ae assay was not completed because of the early termination of the study.", "reportingStatus": "POSTED", "timeFrame": "4 and 5 hours after exercise testing session", "groups": [{"id": "OG000", "title": "Serelaxin-Placebo", "description": "Subjects received serelaxin in Treatment Period 1 and placebo in Treatment Period 2.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion."}, {"id": "OG001", "title": "Placebo-Serelaxin", "description": "Subjects received placebo in Treatment Period 1 and serelaxin in Treatment Period 2.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Log-transformed Concentration of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations Compared to Placebo", "description": "This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.", "populationDescription": "The full analysis set (FAS) consisted of all randomized patients.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline, up to 7 hours after the start of an exercise testing session on treatment period 1 (Day 1) and treatment period 2 (Day 15 +/- 1)", "groups": [{"id": "OG000", "title": "Serelaxin", "description": "Participants receiving serelaxin in Treatment Period 1 and in Treatment Period 2.\n\nEach participant received each of the treatments in randomized order in 2 treatment periods separated by a 15 +/- 1-day washout.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen."}, {"id": "OG001", "title": "Placebo", "description": "Participants receiving placebo in Treatment Period 1 and in Treatment Period 2. Each participant received each of the treatments in randomized order in 2 treatment periods separated by a 15 +/- 1-day washout.\n\nPlacebo was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.5026", "spread": "0.64893"}, {"groupId": "OG001", "value": "13.6217", "spread": "0.60192"}]}]}, {"title": "132 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.5729", "spread": "0.62057"}, {"groupId": "OG001", "value": "13.7076", "spread": "0.61612"}]}]}, {"title": "180 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.5302", "spread": "0.62107"}, {"groupId": "OG001", "value": "13.6777", "spread": "0.61118"}]}]}, {"title": "240 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.5673", "spread": "0.68419"}, {"groupId": "OG001", "value": "13.7011", "spread": "0.58471"}]}]}, {"title": "300 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.6103", "spread": "0.63614"}, {"groupId": "OG001", "value": "13.7129", "spread": "0.57832"}]}]}, {"title": "360 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.6687", "spread": "0.65735"}, {"groupId": "OG001", "value": "13.7213", "spread": "0.57366"}]}]}, {"title": "420 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.6533", "spread": "0.64776"}, {"groupId": "OG001", "value": "13.7399", "spread": "0.57361"}]}]}]}, {"type": "SECONDARY", "title": "Log-transformed Concentration Values of Heart-type Fatty Acid-binding Protein (H-FABP) Concentrations Compared to Placebo", "description": "This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.", "populationDescription": "The full analysis set (FAS) consisted of all randomized patients. Patients were analyzed according to the treatment they had been assigned to at randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline, up to 7 hours after the start of an exercise testing session on treatment period 1 (Day 1) and treatment period 2 (Day 15 +/- 1)", "groups": [{"id": "OG000", "title": "Serelaxin", "description": "Participants receiving serelaxin in Treatment Period 1 and in Treatment Period 2.\n\nEach participant received each of the treatments in randomized order in 2 treatment periods separated by a 15 +/- 1-day washout.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen."}, {"id": "OG001", "title": "Placebo", "description": "Participants receiving placebo in Treatment Period 1 and in Treatment Period 2. Each participant received each of the treatments in randomized order in 2 treatment periods separated by a 15 +/- 1-day washout.\n\nPlacebo was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.8256", "spread": "0.67027"}, {"groupId": "OG001", "value": "8.8810", "spread": "0.64372"}]}]}, {"title": "132 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.8644", "spread": "0.63646"}, {"groupId": "OG001", "value": "8.8409", "spread": "0.67261"}]}]}, {"title": "180 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.7897", "spread": "0.62835"}, {"groupId": "OG001", "value": "8.7955", "spread": "0.62729"}]}]}, {"title": "240 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.7718", "spread": "0.63971"}, {"groupId": "OG001", "value": "8.8662", "spread": "0.58565"}]}]}, {"title": "300 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.7309", "spread": "0.62177"}, {"groupId": "OG001", "value": "8.7202", "spread": "0.65890"}]}]}, {"title": "360 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.7692", "spread": "0.64920"}, {"groupId": "OG001", "value": "8.8088", "spread": "0.59672"}]}]}, {"title": "420 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.7669", "spread": "0.65793"}, {"groupId": "OG001", "value": "8.7329", "spread": "0.63139"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "4", "timeFrame": "Adverse Events are monitored from on or after the time of first administration of study treatment up to 30 days after the last administration were included.", "description": "The safety set consisted of all patients who received any amount of study treatment and had at least one post-baseline safety assessment. 22 participants were included in the safety set because 4 randomized patients did not receive study treatment.", "eventGroups": [{"id": "EG000", "title": "Serelaxin", "description": "Participants receiving serelaxin in Treatment Period 1 and in Treatment Period 2.\n\nEach participant received each of the treatments in randomized order in 2 treatment periods separated by a 15 +/- 1-day washout.\n\nSerelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.", "deathsNumAffected": 0, "deathsNumAtRisk": 20, "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 7, "otherNumAtRisk": 20}, {"id": "EG001", "title": "Placebo", "description": "Participants receiving placebo in Treatment Period 1 and in Treatment Period 2. Each participant received each of the treatments in randomized order in 2 treatment periods separated by a 15 +/- 1-day washout.\n\nPlacebo was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.", "deathsNumAffected": 0, "deathsNumAtRisk": 20, "seriousNumAffected": 1, "seriousNumAtRisk": 20, "otherNumAffected": 6, "otherNumAtRisk": 20}, {"id": "EG002", "title": "Total", "description": "Total", "deathsNumAffected": 0, "deathsNumAtRisk": 22, "seriousNumAffected": 1, "seriousNumAtRisk": 22, "otherNumAffected": 12, "otherNumAtRisk": 22}], "seriousEvents": [{"term": "Haemarthrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Iron deficiency", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 22}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The study was terminated early by Novartis, 19-Apr-2017. Because of the early termination of the study, the validation of the hs-cTnI assay was not completed and the primary efficacy endpoint was not analyzed."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e.,data from all sites)in the clinical trial."}, "pointOfContact": {"title": "Clinical Disclosure Office", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "asFound": "Chronic", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}